secwatch.observer — SEC 8-K summary
======================================

Issuer:     LISATA THERAPEUTICS, INC. (LSTA)
CIK:        0000320017
Form:       8-K
Filed at:   2023-02-06T23:59:59+00:00
Accession:  0000320017-23-000003
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lisata's LSTA201 trial in diabetic kidney disease fails to show consistent kidney function improvement
--------------------------------------------------------------------------------

- Preliminary unaudited cash, equivalents and marketable securities of ~$69.2M as of Dec 31, 2022.
- Phase 1b trial of LSTA201 (CD34+ cell therapy) in 6 DKD patients tolerated but no consistent kidney function improvement.
- Company will evaluate data and determine next steps; no further clinical study committed.
- Corporate presentation attached as Exhibit 99.1 for investor conference use.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000003/0000320017-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/320017/000032001723000003/clbs-20230206.htm
  HTML page:      https://secwatch.observer/filing/0000320017-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer